[{"bbox": [91, 98, 369, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [91, 165, 1558, 971], "category": "Table", "text": "<table><tr><td>2020-21</td><td>Introduced Viral Transport Medium (VTM), Nucleic Acid Extraction Kit and Covid-19 RT-PCR Kit.</td></tr><tr><td>2020-21</td><td>Expanded ELISA product range with HIV, HCV, and HBsAg kits.</td></tr><tr><td>2021-22</td><td>Change of the name of the Company from \"POCT Services Private Limited\" to \"Q-Line Biotech Private Limited\".</td></tr><tr><td>2022-23</td><td>Expansion of office at Naraina Industrial Area, New Delhi.</td></tr><tr><td>2023-24</td><td>Incorporated a Subsidiary Company in the name of \"Q-Line Nutraceuticals Private Limited\".</td></tr><tr><td>2023-24</td><td>Incorporated a Subsidiary Company in the name of \"IQ-Line Private Limited\".</td></tr><tr><td>2023-24</td><td>Incorporated an Associate Company in the name of \"Q-Line Iris Private Limited\".</td></tr><tr><td>2023-24</td><td>Established the manufacturing facility at Plot No. 276, Behtwa, Amausi, Station Road, Sarojni Nagar, Lucknow, Lucknow - 226009, Uttar Pradesh.</td></tr><tr><td>2023-24</td><td>Established the manufacturing facility at Plot No. 3105, Gindan Khera, Amausi Station Road, Nadarganj, Lucknow-226008, Uttar Pradesh.</td></tr><tr><td>2023-24</td><td>Transferred its entire shareholding in \"IQ-Line Private Limited\" which resulted in it no longer being a Subsidiary Company.</td></tr><tr><td>2024-25</td><td>Established the manufacturing facility in 298 and 281, Adjacent Transport Nagar Metro station, Transport Nagar, Lucknow- 226023, Uttar Pradesh.</td></tr><tr><td>2024-25</td><td>Conversion of the Private Limited Company into a Public Limited Company as per the provisions of the Companies Act, 2013.</td></tr><tr><td>2024-25</td><td>Acquired shares in \"Q-line Innovations Private Limited\", making it a Subsidiary Company.</td></tr><tr><td>2024-25</td><td>Transferred its entire shareholding in \"Q-Line Nutraceuticals Private Limited\" which resulted in it no longer being a Subsidiary Company.</td></tr><tr><td>2024-25</td><td>Transferred its majority shareholding in \"POCT Science House Private Limited\" which resulted in it no longer being an Associate Company.</td></tr></table>"}, {"bbox": [91, 1003, 634, 1036], "category": "Section-header", "text": "## Key Awards, Accreditations and Recognitions"}, {"bbox": [91, 1067, 1416, 1099], "category": "Text", "text": "The table below sets forth certain key awards, accreditations, certifications and recognitions received by our Company:"}, {"bbox": [91, 1127, 1558, 1600], "category": "Table", "text": "<table><thead><tr><td>Year/F.Y.</td><td>Awards/ Accreditations/ Certifications/ Recognitions</td></tr></thead><tbody><tr><td>2022-23</td><td>Received the Certificate of Excellence from Boule for outstanding dedication and service to Boule products.</td></tr><tr><td>2023-24</td><td>Received an Appreciation Award at JAI-CON 2023 during the 1st State Level Scientific Conference organized by JAI MLAP Punjab.</td></tr><tr><td>2023-24</td><td>Received the Outstanding Distributor Award 2023 from Shenzhen Lifotronic Technology Co., Ltd. for their professionalism and valuable contribution.</td></tr><tr><td>2023-24</td><td>In-house R&D recognized by Government of India, Ministry of Science and Technology, Department of Scientific and Industrial Research (DSIR).</td></tr><tr><td>2024-25</td><td>Awarded with Certificate of Appreciation for participation in Pharmatech & Health East Africa and Medical & Lab East Africa held in Dar Es Salaam, Tanzania.</td></tr><tr><td>2024-25</td><td>Received the Golden Star Icon Award 2024 for pioneering work in In-Vitro Diagnostics & Associated Equipment.</td></tr><tr><td>2024-25</td><td>Awarded \"Most Promising Company in IVD for Make in India initiative\" at the 15th MT India Healthcare Awards 2025 by Medgate Today Magazine.</td></tr></tbody></table>"}, {"bbox": [91, 1632, 502, 1665], "category": "Section-header", "text": "## Other details about our Company:"}, {"bbox": [91, 1696, 1558, 1793], "category": "Text", "text": "For details of our Company's business, products, technology, launch of key products or services, entry in new geographies or exit from existing markets and our customers, please refer section titled **\"Our Business\"** and **\"Management's Discussion and Analysis of Financial Conditions and Results of Operations\"** on pages 123 and 246 respectively of this Draft Red Herring Prospectus."}, {"bbox": [91, 1825, 472, 1858], "category": "Section-header", "text": "## Capital Raising (Debt / Equity):"}, {"bbox": [91, 1888, 1558, 1984], "category": "Text", "text": "For details in relation to our capital raising activities through equity, please refer to the chapter titled **\"Capital Structure\"** beginning on page 71 of the Draft Red Herring Prospectus. For details of our Company's debt facilities, see **\"Statement of Financial Indebtedness\"** on page 241 of the Draft Red Herring Prospectus."}, {"bbox": [91, 2016, 888, 2049], "category": "Section-header", "text": "## Changes in activities of our Company during the last five (5) Years:"}, {"bbox": [91, 2080, 1558, 2145], "category": "Text", "text": "There has not been any change in the activity of our Company during the last five (5) years preceding the date of this Draft Red Herring Prospectus."}]